SEC subpoenas, FDA approvals, and FTC pricing deadline — September 1–7, 2026
A concise, calendar-ready digest of 12 SEC, FDA, and FTC developments from September 1–7, 2026, with affected parties, procedural status, operational implications, and original agency links.
The September 1–7, 2026 window produced 12 developments across the SEC, FDA, and FTC: five SEC matters, five FDA actions, and two FTC actions. The practical work is to calendar three fixed dates, review the affected controls, and separate allegations, proposed measures, approvals, and final orders. No independently verified causal stock-price move was identified; the supported implications are compliance, operational, and procedural.
At a glance
| Agency | Development | Status or amount | Next action |
|---|---|---|---|
| SEC | Hanf, Phan, and Pacific Private Money Group | Complaint and proposed settlement; more than $80 million raised from about 190 investors; more than $7 million allegedly misappropriated | Review private-fund controls, investor communications, and related-party payments. 1 |
| SEC | Institutional Shareholder Services | SEC seeks an order compelling compliance with an administrative subpoena; monetary relief pending | Preserve proxy-advice and voting records, and monitor the Eastern District of Pennsylvania proceeding. 2 |
| SEC | Transfer-agent rules | Proposed rule; comments close November 3, 2026 | Map tokenized-securities, electronic-record, safeguarding, and restrictive-legend controls. 3 |
| SEC | Investment-adviser pay-to-play rule | Proposed rescission; Rule 206(4)-5 remains operative; deadline pending Federal Register publication | Keep current pay-to-play controls and prepare a comment position. 4 |
| SEC | 24-hour trading roundtable | Public event on September 17, 2026; no rule change yet | Track exchange, broker, surveillance, settlement, cyber, staffing, and liquidity implications. 5 |
| FDA | Etcamah (camizestrant) | Accelerated approval for HR-positive/HER2-negative, ESR1-mutated advanced breast cancer | Review companion-diagnostic, label, confirmatory-study, and cardiac-risk workflows. 6 |
| FDA | Zanvastro (zilganersen) | First FDA-approved treatment for Alexander disease | Update product, administration, pediatric-use, and adverse-event procedures. 7 |
| FDA | Capstar and generic nitenpyram | EUA for prevention and treatment of New World screwworm in dogs and cats | Confirm species, age, weight, OTC labeling, and treatment protocols. 8 |
| FDA | Neonatal starter parenteral nutrition | Immediately effective temporary compounding policies under Sections 503A and 503B | Hospitals should identify qualified compounders and verify supply continuity. 9 |
| FDA | Dental Technologies | Corrective-action closeout for a November 30, 2021 warning letter | Maintain sustained compliance and retain evidence supporting the corrections. 10 |
| FTC | Nuvei and subsidiaries | FTC complaint and proposed settlement; $485 million payment announced; merchant-screening requirements proposed | Review merchant onboarding, high-risk classification, chargeback, and escalation controls. 11 |
| FTC | Personalized pricing | Comment deadline extended to September 25, 2026 | Inventory individualized pricing, data inputs, disclosures, consent, and vendor controls. 12 |
SEC
Hanf and Phan: private-fund money and alleged Ponzi-like payments
On September 1, the SEC charged Mark D. Hanf and Hoai-Nam Chu Phan, executives associated with Pacific Private Money Group, in a federal complaint concerning more than $80 million raised from about 190 mostly retail investors. The SEC alleges that Hanf and Phan used new investor money to make Ponzi-like payments to earlier investors and that Hanf misappropriated more than $7 million. The SEC also announced parallel criminal charges. 1
The SEC filed the related litigation release on September 1 and published Litigation Release No. 26627 on September 4. The proposed relief includes injunctions, disgorgement, interest, and civil penalties, with the financial amounts to be determined later. The matter remains a filed enforcement case, and the proposed settlement is subject to court approval. 13
Private-fund managers, administrators, and diligence teams should test cash-use controls, investor statements, redemption funding, related-party transactions, and segregation of investor assets. The next procedural step is court treatment of the requested relief and continued criminal proceedings.
ISS subpoena enforcement: proxy-advice records remain in dispute
On September 4, the SEC asked the Eastern District of Pennsylvania to compel Institutional Shareholder Services, Inc. to comply with an administrative subpoena issued on July 21, 2026. The requested records concern proxy recommendations and voting. The SEC states that it has not concluded that ISS violated the securities laws. 2
The proceeding seeks subpoena enforcement, and the release identifies no monetary relief. ISS and other proxy-advice participants should preserve recommendation methodology, client communications, voting records, and data supplied to the SEC. The next action is the court's decision on the SEC's enforcement request.
Transfer agents: proposed rules reach tokenized securities and electronic records
The SEC announced the proposal on September 1. The Federal Register published Transfer Agent Rules on September 4, as document 2026-18190, 91 FR 56946, Release No. 34-106246, File No. S7-2026-30. Comments close on November 3, 2026. 314
The proposal would update Forms TA-1 and TA-2 and revise rules on registration, transfer processing, recordkeeping, safeguarding, electronic records, distributed-ledger and tokenized securities, and restrictive legends. Transfer agents, issuers, broker-dealers, securities intermediaries, and technology vendors should map the proposed requirements against custody, record-retention, cyber, and exception-handling controls. The calendar action is to submit comments by November 3.
Pay-to-play: rescission proposal leaves the current rule in place
On September 3, the SEC proposed rescinding Advisers Act Rule 206(4)-5 and related recordkeeping requirements. The proposal would remove the federal rule that restricts certain investment-adviser advisory business after political contributions to officials who can influence the selection of advisers, along with related recordkeeping provisions. 4
The SEC release says comments remain open for 60 days after Federal Register publication. A Federal Register publication date and exact deadline were not available as of September 7, so the item stays out of the fixed-date calendar. Rule 206(4)-5 remains operative while the proposal is pending. Investment advisers, covered associates, municipal-finance teams, and compliance officers should continue contribution preclearance, covered-official screening, and recordkeeping, while preparing a comment position. The SEC's proposal is available in Release IA-6994. 15
24-hour trading: September 17 roundtable
The SEC announced the agenda and panelists on September 1 for a public roundtable on preparations for 24-hour trading. The event is scheduled for September 17, 2026, from 10:00 a.m. to 4:00 p.m. Eastern time. The agenda covers exchange and broker readiness, overnight surveillance, closing prices, clearance and settlement, investor protection, systems and cyber resilience, staffing, liquidity, and capital formation. 516
The event is a monitoring item rather than a rule change. Exchanges, broker-dealers, clearing firms, market makers, and listed issuers should use the September 17 discussion to track possible changes to operating windows, surveillance coverage, settlement staffing, resiliency testing, and liquidity arrangements.
FDA
Etcamah: accelerated approval tied to an ESR1 test
On September 4, the FDA granted accelerated approval to AstraZeneca's Etcamah (camizestrant) for adults with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer with an ESR1 mutation detected by an FDA-authorized test. The treatment is used with a CDK4/6 inhibitor. The FDA also authorized Guardant360 CDx as a companion diagnostic. Median progression-free survival was 16 months versus 9.2 months in the comparator arm. 6
The approval requires confirmatory studies. The label includes a boxed warning about irregular heart rhythm with certain medications and warnings concerning bradycardia and fetal harm. AstraZeneca, diagnostic providers, oncology practices, and pharmacovigilance teams should align mutation testing, companion-diagnostic distribution, drug-interaction review, confirmatory-study tracking, and safety communications with the approved label.
Zanvastro: first FDA-approved treatment for Alexander disease
On September 3, the FDA approved Zanvastro (zilganersen) from Ionis Pharmaceuticals as the first FDA-approved treatment for Alexander disease. The antisense oligonucleotide reduces abnormal GFAP production and is injected into the spinal canal every three months. The indication covers pediatric and adult patients; the infant population rests on limited data and pharmacokinetic modeling. 7
Common adverse effects include vomiting, back pain, cough, headache, and post-lumbar-puncture syndrome. Aseptic meningitis has been reported. Ionis, specialty pharmacies, neurologists, and treatment centers should update administration, pediatric consent, lumbar-puncture, monitoring, and adverse-event procedures.
Capstar and generic nitenpyram: dog and cat screwworm EUA
On September 3, the FDA issued emergency use authorizations for Capstar and generic nitenpyram tablets to prevent and treat New World screwworm myiasis in dogs, puppies, cats, and kittens at least four weeks old and at least two pounds. Generic nitenpyram had previously been authorized for treatment only; the new authorization adds prevention. The products are available over the counter, with sponsors Sergeant's Pet Care Products LLC and Felix Pharmaceuticals Pvt. Ltd. 8
Veterinary practices, distributors, shelters, and pet owners should verify species, age, weight, indication, dosing, and fact-sheet instructions before use. The authorization changes the permitted use of the products; it does not create a general authorization for animals outside the stated population.
Neonatal starter parenteral nutrition: temporary compounding access
On September 4, the FDA issued immediately effective temporary policies under Sections 503A and 503B for compounding certain neonatal starter parenteral-nutrition products. Children's hospitals had raised a potential supply-gap concern after two outsourcing facilities shut down. 9
The immediate task is operational: hospitals, pharmacies, and qualified compounders should confirm product availability, facility eligibility, formulation controls, procurement lead times, and continuity plans. The policy addresses access during the supply concern; it does not remove the need to verify compounding and quality requirements.
Dental Technologies: corrective-action closeout
The FDA posted a follow-up page for Dental Technologies Inc. on September 2 concerning a warning letter issued on November 30, 2021. FDA stated that the firm's corrective actions appeared to have adequately addressed the cited violations, while expecting sustained compliance and reserving future enforcement authority. 10
The page records a corrective-action closeout, not a new warning allegation. Dental Technologies should maintain the records supporting the corrections, monitor sustained compliance, and preserve evidence for future FDA inspections.
FTC
Nuvei: proposed $485 million payment and merchant-screening controls
On September 4, the FTC announced a complaint and proposed settlement involving Nuvei Corporation, Nuvei International Group Limited, Nuvei Limited, SafeCharge Digital Limited, and Nuvei Technologies, Inc. The FTC alleges that the payment-processing companies knowingly processed transactions for merchants engaged in fraudulent activity. The proposed settlement calls for a $485 million payment and robust merchant-screening requirements. 11
The FTC complaint, filed on September 3, alleges that Nuvei entities processed more than $30 million in credit-card charges for the Reimage tech-support scheme and used multiple merchant accounts and processors in ways that helped spread transaction volume and chargebacks. The complaint also describes alleged processing for other high-risk merchants and asks the court for a permanent injunction and monetary relief. 17
The case remains a complaint and proposed settlement, so the allegations and proposed relief await the court's treatment. Payment processors, acquirers, payment facilitators, and fintech compliance teams should review merchant applications, beneficial-owner checks, merchant-category codes, prohibited-industry rules, chargeback escalation, account splitting, and termination decisions. The next step is court consideration of the proposed settlement and implementation of any final order.
Personalized pricing: comment deadline moves to September 25
On September 3, the FTC extended the public-comment period for its proposed enforcement policy statement on personalized pricing by seven days. Comments are now due September 25, 2026. The statement addresses the use of personal data to set a price according to what a company believes an individual consumer is willing to spend. 12
The underlying proposal, issued on August 19, says that businesses should clearly and conspicuously disclose when a price is personalized, the basis for the personalization, and the types of data used when consumers reasonably expect a generally available price. The proposal also discusses potential deception, unfairness, and data-collection or consent concerns under Section 5 of the FTC Act. The proposal is a policy statement, not a trade rule or a binding legal determination. 18
Retailers, marketplaces, loyalty-program operators, pricing-analytics providers, and vendors should inventory individualized prices, discounts, fees, and recommendations; identify each personal-data input; review disclosure and consent language; and preserve vendor documentation. The fixed calendar action is to submit comments by September 25.
Action calendar and market signal
| Date | Action |
|---|---|
| September 17, 2026 | Attend or monitor the SEC roundtable on preparations for 24-hour trading. 16 |
| September 25, 2026 | Submit comments on the FTC's proposed personalized-pricing policy statement. 12 |
| November 3, 2026 | Submit comments on the SEC's proposed transfer-agent rules. 3 |
The SEC pay-to-play proposal remains on a pending timetable until Federal Register publication supplies the 60-day comment period's starting point. The Nuvei, ISS, Hanf/Phan, and FDA corrective-action matters carry procedural or response steps tied to court action, receipt, confirmatory studies, or continuing compliance. Those trigger-based steps belong in matter-specific calendars.
The agencies' releases supplied no independently verified causal market reaction for these developments. Portfolio and finance teams should therefore treat the direct implications as exposure mapping, deadline management, control testing, product and label implementation, supply continuity, and procedural monitoring.
Fuentes de referencia
- 1
- 2
- 3Transfer Agent Rules
federalregister.gov
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15SEC proposed rescission PDF
sec.gov
- 16
- 17
- 18
Este contenido lo produjo un canal automáticamente. Con una sola frase, Neodrop puede seguir produciendo para ti.